Gilead Sciences’ (GILD) CCO Mercier sells $354k in stock

Chief Commercial Officer of Gilead Sciences (NASDAQ:GILD), Johanna Mercier, sold 3,000 shares of common stock on October 15, 2025, at a price of $118.08, totaling $354,240. The transaction comes as the biotechnology giant, with a market capitalization of $146 billion, trades near its 52-week high of $121.83, having delivered an impressive 30% return year-to-date.

Following the transaction, Mercier directly owns 110,193 shares of Gilead Sciences. According to InvestingPro analysis, the company shows strong fundamentals with 10 consecutive years of dividend increases and maintains a healthy 2.7% dividend yield. For detailed insights and more exclusive tips about GILD, investors can access the comprehensive Pro Research Report, available to InvestingPro subscribers.

The sale was executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. The company’s next earnings report is scheduled for October 30, 2025, with analysts maintaining a bullish outlook and price targets ranging from $100 to $145 per share.

In other recent news, Gilead Sciences will present significant data for its cancer drug Trodelvy at the European Society for Medical Oncology 2025 Congress. The Phase 3 ASCENT-03 study showed that Trodelvy provided a statistically significant improvement in progression-free survival for patients with metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors. Additionally, RBC Capital has raised its price target for Gilead Sciences to $100, citing the promising early launch of its new drug Yeztugo, which may outperform initial sales expectations. Meanwhile, Bernstein has reiterated its Outperform rating with a $135 price target following Gilead’s settlement of patent lawsuits, extending exclusivity for its HIV treatment Biktarvy until April 2036. Needham also maintained a Buy rating with a $133 price target, emphasizing the potential of Gilead’s inflammation pipeline for long-term growth. The settlement agreements with generic manufacturers Lupin, Cipla, and Laurus Labs ensure that no generic versions of Biktarvy will enter the U.S. market before April 2036. These developments highlight Gilead’s strategic maneuvers in both oncology and HIV treatment markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.